Celon Pharma S.A. (WSE:CLN)

Celon Pharma Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	32.36	82.9	147.8	43.98	66.69
Short-Term Investments	82.18	81.72	79.76	-	-
Cash & Short-Term Investments	114.54	164.62	227.55	43.98	66.69
Cash Growth	-30.42%	-27.65%	417.42%	-34.06%	-54.94%
Accounts Receivable	32.79	27.11	24.67	32.53	39.18
Other Receivables	15.45	6.59	2.57	9.49	6.6
Receivables	48.24	33.7	27.25	42.02	45.78
Inventory	26.41	38.39	23.38	29.76	30.06
Other Current Assets	0.56	0.87	0.53	3.48	1.04
Total Current Assets	189.75	237.58	278.7	119.24	143.58
Property, Plant & Equipment	333.8	341.59	316.57	313.8	230.08
Long-Term Investments	11.42	13.25	38.12	12.87	48.53
Other Intangible Assets	14.29	21.15	27.81	38.38	2.08
Long-Term Deferred Tax Assets	19.05	28.14	31.94	27.17	11.5
Long-Term Deferred Charges	0.68	0.68	1.36	2.72	4.08
Other Long-Term Assets	0.32	0.38	12.64	17.7	151.5
Total Assets	569.31	642.76	707.14	531.89	591.35
Accounts Payable	10.51	17.47	11.87	18.42	7.36
Accrued Expenses	7.39	6.8	3.11	6.77	1.49
Short-Term Debt	12.75	-	-	12.84	-
Current Portion of Leases	7.13	19.43	6.56	3.49	1.47
Current Income Taxes Payable	-	-	-	-	1.02
Current Unearned Revenue	31.09	56.42	55.83	45.78	3.11
Other Current Liabilities	17.48	16.32	8.99	26.86	11.53
Total Current Liabilities	86.34	116.44	86.36	114.15	25.98
Long-Term Leases	5.71	7.39	8.35	9.16	0.19
Long-Term Unearned Revenue	22.88	25.62	29.85	39.67	108.62
Long-Term Deferred Tax Liabilities	3.01	1.32	6.04	-	11.51
Other Long-Term Liabilities	5.81	12.35	22.53	24.38	0
Total Liabilities	123.75	163.12	153.14	187.36	146.31
Common Stock	5.11	5.1	5.1	4.5	4.5
Additional Paid-In Capital	543.23	587.1	613.51	393.12	234.45
Retained Earnings	-108.64	-119.79	-91.67	-58.57	172.34
Comprehensive Income & Other	5.85	7.23	27.07	5.48	33.75
Shareholders' Equity	445.56	479.65	554	344.53	445.04
Total Liabilities & Equity	569.31	642.76	707.14	531.89	591.35
Total Debt	25.59	26.82	14.92	25.48	1.66
Net Cash (Debt)	88.95	137.8	212.63	18.5	65.03
Net Cash Growth	-35.45%	-35.19%	1049.56%	-71.56%	-56.06%
Net Cash Per Share	1.74	2.70	4.55	0.41	1.45
Filing Date Shares Outstanding	51.06	51.04	51	45	45
Total Common Shares Outstanding	51.06	51.04	51	45	45
Working Capital	103.41	121.14	192.34	5.1	117.6
Book Value Per Share	8.73	9.40	10.86	7.66	9.89
Tangible Book Value	431.26	458.5	526.19	306.16	442.96
Tangible Book Value Per Share	8.45	8.98	10.32	6.80	9.84
Land	6.35	6.35	6.35	6.35	6.35
Buildings	146.4	146.35	146.08	173.5	54.94
Machinery	198.61	190.43	177.34	164.34	148.3
Construction In Progress	79.95	74.3	50.63	31.5	95.4

Source: S&P Global Market Intelligence. Standard template. Financial Sources.